Aims/Objectives
To quantify prevalence, treatment eligibility and postoperative survival in patients with AS.
Method
A systematic search was conducted across PubMed and EMBASE for studies evaluating prevalence, severity, decision-making and survival in AS patients. Studies were selected using a priori defined criteria reviewed by two independent investigators. Prevalence rates [95%CI] were calculated and pooled using fixed and random-effects models (statistical heterogeneity evaluated via X2 and I2). Subsequently, Monte Carlo methods with beta distributions and 2012 population data were utilised to assess eligibility per treatment option (using ESC indications).
Results
Fifty-four studies were included encompassing 52,951 patients across 5 domains: prevalence, severity, symptom status, treatment and outcome. Pooled prevalence in the general population aged 55-74yrs and >75yrs was 2.9% [1. ,187,586 [6,988,043-11,629,367] Europeans aged ≤55yrs with AS. Of these, 1, 984, 666 [1, 494, 550, 594] have severe AS with 1,178,766 [878,802-1,528,812] eligible for SAVR and 234, 934 [149, 960 ] eligible for TAVR.
Discussion/Conclusion
Within current ESC guidelines, approximately 1.2 million Europeans aged ≤55yrs are candidates for SAVR with an additional 230,000 patients aged ≤75yrs eligible for TAVR.
